Prenatal New Born Genetic Testing

Prenatal and New-born Genetic Testing Market (PCR, FISH, aCGH, NIPT and MSS) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019

  • Rep Id : TMRGL1744
  • Published On : Mar 2014
  • No. of Pages : 87
  • Category : Healthcare

 
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Sources
1.4 List of Abbreviations
 
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Prenatal and Newborn Genetic Testing Market (2012 & 2019)
2.2 Global Prenatal and Newborn Genetic Testing Market, by Segments, 2012 (USD Million)
 
Chapter 3 Prenatal and Newborn Genetic Testing Market Overview
3.1 Introduction and Market Definition
3.2 Future Market Outlook
3.3 Regulatory and Reimbursement Scenario for Prenatal and Newborn Screening
3.4 Market Dynamics
      3.4.1 Drivers
      3.4.2 Restraints
      3.4.3 Market Opportunities
3.5 Porter’s Five Forces Analysis: Global Prenatal and Newborn Genetic Testing Market
      3.5.1 Bargaining Power of Suppliers
      3.5.2 Bargaining Power of Buyers
      3.5.3 Threat of Substitutes
      3.5.4 Threat of New Entrants
      3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis
 
Chapter 4 Prenatal and Newborn Genetic Testing Market, by Technology
4.1 Overview
      4.1.1 Global Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 – 2019 (USD Million)
4.2 Diagnostic Techniques
      4.2.1 Global Diagnostic Techniques Market Revenue, by Types, 2012 – 2019 (USD Million)
      4.2.2 Polymerase Chain Reaction (PCR)
      4.2.3 Fluorescence In-Situ Hybridization  (FISH)
      4.2.4 Array-Comparative Genomic Hybridization (aCGH)
4.3 Screening Methods
      4.3.1 Global Screening Methods Market Revenue, by Types, 2012 – 2019 (USD Million)
      4.3.2 Non-invasive Prenatal Tests (MaterniT21 PLUS, Verifi, Harmony, Panorama, NIFTY, PrenaTest and Bambni Test)
      4.3.3 Maternal Serum Screening (MSS)
 
Chapter 5 Prenatal and Newborn Genetic Testing Market, by Geography
5.1 Overview
      5.1.1 Global Prenatal and Newborn Genetic Testing Market Revenue, by Geography2012 – 2019 (USD Million)
5.2 North America
      5.2.1 North America Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
      5.2.2 North America Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
      5.2.3 North America Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
5.3 Europe
      5.3.1 Europe Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
      5.3.2 Europe Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
      5.3.3 Europe Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
5.4 Asia - Pacific
      5.4.1 Asia-Pacific Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
      5.4.2 Asia-Pacific Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
      5.4.3 Asia-Pacific Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
5.5 Rest of the World (RoW)
      5.5.1 RoW Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
      5.5.2 RoW Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
      5.5.3 RoW Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
 
Chapter 6 Competitive Landscape
6.1 Market Share Analysis, by Key Players, 2012 (%)
 
Chapter 7 Recommendations
7.1 Market Strategy for Success
      7.1.1 Focus on forming alliances with diagnostic service providers in Asia-Pacific countries
      7.1.2 Emphasis on improving technology in order to increase accuracy, reduce the duration of result generation and price
7.2 Barriers and Future Assumptions
      7.2.1 Lack of awareness about prenatal and newborn genetic testing in some Asian countries
      7.2.2 Regulatory compliance and ethical issues
 
Chapter 8 Company Profiles
8.1 Agilent Technologies, Inc.
      8.1.1 Company Overview
      8.1.2 Financial Overview
      8.1.3 Product Portfolio
      8.1.4 Business Strategies
      8.1.5 Recent Developments
8.2 Ariosa Diagnostics, Inc.
      8.2.1 Company Overview
      8.2.2 Financial Overview
      8.2.3 Product Portfolio
      8.2.4 Business Strategies
      8.2.5 Recent Developments
8.3 Bio-Rad Laboratories, Inc.
      8.3.1 Company Overview
      8.3.2 Financial Overview
      8.3.3 Product Portfolio
      8.3.4 Business Strategies
      8.3.5 Recent Developments
8.4 Illumina, Inc.
      8.4.1 Company Overview
      8.4.2 Financial Performance
      8.4.3 Product Portfolio
      8.4.4 Business Strategies
      8.4.5 Recent Developments
8.5 Laboratory Corporation of America Holdings (LabCorp)
      8.5.1 Company Overview
      8.5.2 Financial Overview
      8.5.3 Product Portfolio
      8.5.4 Business Strategies
      8.5.5 Recent Developments
8.6 Natera, Inc.
      8.6.1 Company Overview
      8.6.2 Financial Overview
      8.6.3 Product Portfolio
      8.6.4 Business Strategies
      8.6.5 Recent Developments
8.7 PerkinElmer, Inc.
      8.7.1 Company Overview
      8.7.2 Financial Overview
      8.7.3 Product Portfolio
      8.7.4 Business Strategies
      8.7.5 Recent Developments
8.8 Sequenom, Inc.
      8.8.1 Company Overview
      8.8.2 Financial Overview
      8.8.3 Product Portfolio
      8.8.4 Business Strategies
      8.8.5 Recent Developments

List of Tables
 
TABLE 1 Market Snapshot: Global Prenatal and Newborn Genetic Testing Market (2012 & 2019)
TABLE 2 Technological Approach for Non-Invasive Prenatal Screening Tests
TABLE 3 Global Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 – 2019 (USD Million)
TABLE 4 Global Diagnostic Techniques Market Revenue, by Types, 2012 – 2019 (USD Million)
TABLE 5 Global Screening Methods Market Revenue, by Types, 2012 – 2019 (USD Million)
TABLE 6 Global Prenatal and Newborn Genetic Testing Market Revenue, by Geography, 2012 – 2019 (USD Million)
TABLE 7 North America Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
TABLE 8 North America Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
TABLE 9 North America Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
TABLE 10 Europe Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
TABLE 11 Europe Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
TABLE 12 Europe Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
TABLE 13 Asia-Pacific Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
TABLE 14 Asia-Pacific Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
TABLE 15 Asia-Pacific Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
TABLE 16 RoW Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
TABLE 17 RoW Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
TABLE 18 RoW Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)

List of Figures
 
FIG. 1 Prenatal and Newborn Genetic Testing: Market Segmentation
FIG. 2 Global Prenatal and Newborn Genetic Testing Market, by Segments, 2012 (USD Million)
FIG. 3 Adoption Curve Analysis for Genetic Testing Market
FIG. 4 Porter’s Five Forces Analysis: Global Prenatal and Newborn Genetic Testing Market
FIG. 5 Market Attractiveness Analysis: Global Prenatal and Newborn Genetic Testing Market, 2012
FIG. 6 Global PCR Market Revenue, 2012 – 2019 (USD Million)
FIG. 7 FISH Procedural Steps
FIG. 8 Global FISH Market Revenue, 2012 – 2019 (USD Million)
FIG. 9 Global aCGH Market Revenue, 2012 – 2019 (USD Million)
FIG. 10 Global NIPT Market Revenue, 2012 – 2019 (USD Million)
FIG. 11 Global MSS Market Revenue, 2012 – 2019 (USD Million)
FIG. 12 Global Prenatal and Newborn Genetic Testing: Market Share, by Key Players, 2012 (%)
FIG. 13 Annual Sales: Agilent Technologies, Inc., 2010 – 2012 (USD Million)
FIG. 14 Annual Sales: Bio-Rad Laboratories, Inc., Clinical Diagnostics Segment, 2010 – 2012 (USD Million)
FIG. 15 Annual Sales: Illumina, Inc., 2010 – 2012 (USD million)
FIG. 16 Annual Sales: LabCorp, 2010– 2012 (USD Million)
FIG. 17 Annual Sales: PerkinElmer, Inc. (Human Health Segment), 2010 – 2012 (USD Million)
FIG. 18 Annual Sales: Sequenom Inc., 2010–2012 (USD Million)